SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME
The current clinical guidelines for the treatment of patients with acute coronary syndrome (ACS) claim that simultaneous use of two drugs that inhibit platelet activity is mandatory for most patients. This approach known as dual antiplatelet therapy (DAT), in view of the similarity of the mechanisms...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2017-05-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/108 |
| _version_ | 1826572481986560000 |
|---|---|
| author | A. D. Erlikh |
| author_facet | A. D. Erlikh |
| author_sort | A. D. Erlikh |
| collection | DOAJ |
| description | The current clinical guidelines for the treatment of patients with acute coronary syndrome (ACS) claim that simultaneous use of two drugs that inhibit platelet activity is mandatory for most patients. This approach known as dual antiplatelet therapy (DAT), in view of the similarity of the mechanisms of the disease development, should be used in both ACS with ST elevation (STE-ACS) and in ACS without ST elevation (non-STE-ACS). In both cases, DAT should combine acetylsalicylic acid (ASA) with a P2Y12 receptor antagonist (ticagrelor, prasugrel or clopidogrel). For Russia, where prasugrel is not registered, the most preferable DAT is the combination of ASA with ticagrelor which has outperformed clopidogrel in terms of efficacy in the PLATO trial. [1] |
| first_indexed | 2024-04-10T03:59:01Z |
| format | Article |
| id | doaj.art-10e625d1e03146cb817393894c2249e8 |
| institution | Directory Open Access Journal |
| issn | 2307-1109 2658-5952 |
| language | Russian |
| last_indexed | 2025-03-14T12:27:43Z |
| publishDate | 2017-05-01 |
| publisher | «REMEDIUM GROUP» Ltd. |
| record_format | Article |
| series | Атеротромбоз |
| spelling | doaj.art-10e625d1e03146cb817393894c2249e82025-03-02T09:27:28Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522017-05-0101445210.21518/2307-1109-2017-1-44-52102SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROMEA. D. Erlikh0City Clinical Hospital No. 29 named after N.E. BaumanThe current clinical guidelines for the treatment of patients with acute coronary syndrome (ACS) claim that simultaneous use of two drugs that inhibit platelet activity is mandatory for most patients. This approach known as dual antiplatelet therapy (DAT), in view of the similarity of the mechanisms of the disease development, should be used in both ACS with ST elevation (STE-ACS) and in ACS without ST elevation (non-STE-ACS). In both cases, DAT should combine acetylsalicylic acid (ASA) with a P2Y12 receptor antagonist (ticagrelor, prasugrel or clopidogrel). For Russia, where prasugrel is not registered, the most preferable DAT is the combination of ASA with ticagrelor which has outperformed clopidogrel in terms of efficacy in the PLATO trial. [1]https://www.aterotromboz.ru/jour/article/view/108acute coronary syndromedual antiplatelet therapyacetylsalicylic acidticagrelor |
| spellingShingle | A. D. Erlikh SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME Атеротромбоз acute coronary syndrome dual antiplatelet therapy acetylsalicylic acid ticagrelor |
| title | SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME |
| title_full | SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME |
| title_fullStr | SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME |
| title_full_unstemmed | SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME |
| title_short | SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME |
| title_sort | some aspects of improving adherence to dual antithrombotic therapy after acute coronary syndrome |
| topic | acute coronary syndrome dual antiplatelet therapy acetylsalicylic acid ticagrelor |
| url | https://www.aterotromboz.ru/jour/article/view/108 |
| work_keys_str_mv | AT aderlikh someaspectsofimprovingadherencetodualantithrombotictherapyafteracutecoronarysyndrome |